Buket Kin Tekce1, Ummugul Uyeturk2, Hikmet Tekce3, Ugur Uyeturk4, Gulali Aktas5, Akcan Akkaya6. 1. Department of Medical Biochemistry, Faculty of Medicine, Abant Izzet Baysal University, Bolu, Turkey btekce@yahoo.com. 2. Department of Medical Oncology, Faculty of Medicine, Abant Izzet Baysal University, Bolu, Turkey. 3. Department of Nephrology, Faculty of Medicine, Abant Izzet Baysal University, Bolu, Turkey. 4. Department of Urology, Faculty of Medicine, Abant Izzet Baysal University, Bolu, Turkey. 5. Department of Internal Medicine, Faculty of Medicine, Abant Izzet Baysal University, Bolu, Turkey. 6. Department of Anaesthesiology and Reanimation, Faculty of Medicine, Abant Izzet Baysal University, Bolu, Turkey.
Abstract
BACKGROUND: It is not possible to diagnose acute kidney injury (AKI) in early stages with traditional biomarkers. Kidney injury molecule-1 (KIM-1) is a novel biomarker promising the diagnosis of AKI in early stages. We studied whether urinary and serum KIM-1 (KIM-1 U and KIM-1 S ) concentrations were useful in predicting cisplatin-induced AKI in early stages. METHODS: We prospectively analysed 22 patients on cisplatin treatment. KIM-1 S and KIM-1 U concentrations were assessed in the samples of the patients on four different time periods (before treatment [BT], first [AT1], third [AT3] and fifth [AT5] day after treatment). RESULTS: KIM-1 U concentrations on the first day after cisplatin treatment in patients with AKI were significantly increased compared to both KIM-1 U concentrations of the same patients BT (P=0.009) and to AT1-KIM-1 U concentrations of the patients without AKI (P=0.008). A receiver operating characteristic analysis revealed that AT1-KIM-1 U concentrations may predict AKI with an 87.5% sensitivity and 93.3% specificity (area under the curve=0.94). KIM-1 S concentrations were not significantly changed between BT and AT periods. CONCLUSIONS: KIM-1 U concentrations may predict cisplatin-induced AKI in early stages with high sensitivity and specificity.
BACKGROUND: It is not possible to diagnose acute kidney injury (AKI) in early stages with traditional biomarkers. Kidney injury molecule-1 (KIM-1) is a novel biomarker promising the diagnosis of AKI in early stages. We studied whether urinary and serum KIM-1 (KIM-1 U and KIM-1 S ) concentrations were useful in predicting cisplatin-induced AKI in early stages. METHODS: We prospectively analysed 22 patients on cisplatin treatment. KIM-1 S and KIM-1 U concentrations were assessed in the samples of the patients on four different time periods (before treatment [BT], first [AT1], third [AT3] and fifth [AT5] day after treatment). RESULTS:KIM-1 U concentrations on the first day after cisplatin treatment in patients with AKI were significantly increased compared to both KIM-1 U concentrations of the same patientsBT (P=0.009) and to AT1-KIM-1 U concentrations of the patients without AKI (P=0.008). A receiver operating characteristic analysis revealed that AT1-KIM-1 U concentrations may predict AKI with an 87.5% sensitivity and 93.3% specificity (area under the curve=0.94). KIM-1 S concentrations were not significantly changed between BT and AT periods. CONCLUSIONS:KIM-1 U concentrations may predict cisplatin-induced AKI in early stages with high sensitivity and specificity.
Authors: Maya Sterling; Zubaida Al-Ismaili; Kelly R McMahon; Melissa Piccioni; Michael Pizzi; Theresa Mottes; Larry C Lands; Sharon Abish; Adam J Fleming; Michael R Bennett; Ana Palijan; Prasad Devarajan; Stuart L Goldstein; Maureen M O'Brien; Michael Zappitelli Journal: Pediatr Blood Cancer Date: 2017-04-18 Impact factor: 3.167
Authors: Danielle Carvalho Pedrosa; Fernanda Macedo de Oliveira Neves; Gdayllon Cavalcante Meneses; Gabriela Pinheiro Gomes Wirtzbiki; Carlos Artur da Costa Moraes; Alice Maria Costa Martins; Alexandre Braga Libório Journal: Pediatr Nephrol Date: 2015-08-07 Impact factor: 3.714
Authors: Asaf Lebel; Hayton Chui; Kelly R McMahon; Yong Jin Lim; Joseph Macri; Stella Wang; Prasad Devarajan; Tom D Blydt-Hansen; Michael Zappitelli; Bradley L Urquhart Journal: J Clin Pharmacol Date: 2021-04-15 Impact factor: 3.126